Cyprotex PLC is a holding company. The Company and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. Its in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. It operates mainly in North America, Mainland Europe and the United Kingdom. It serves pharmaceutical, biotech, cosmetics, personal care, household products, chemical, agrochemical and tobacco markets. Its subsidiaries include Cyprotex Discovery Limited and Cyprotex US, LLC.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:CRX
- CUSIP: N/A
- Web: www.cyprotex.com/
- 50 Day Moving Avg: GBX 158.05
- 200 Day Moving Avg: GBX 139.40
- 52 Week Range: GBX 79.22 - GBX 160.50
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Net Margins: 33.85%
- Return on Assets: 36.87%
- Average Volume: 21,791 shs.
Frequently Asked Questions for Cyprotex plc (LON:CRX)
What is Cyprotex plc's stock symbol?
Cyprotex plc trades on the London Stock Exchange (LON) under the ticker symbol "CRX."
Who are some of Cyprotex plc's key competitors?
Some companies that are related to Cyprotex plc include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI) and Nektar Therapeutics (NKTR).
How do I buy Cyprotex plc stock?
Shares of Cyprotex plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Cyprotex plc's stock price today?
MarketBeat Community Rating for Cyprotex plc (LON CRX)MarketBeat's community ratings are surveys of what our community members think about Cyprotex plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cyprotex plc stock can currently be purchased for approximately GBX 160.50.
Consensus Ratings for Cyprotex plc (LON:CRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cyprotex plc (LON:CRX)
(Data available from 7/22/2015 forward)
|11/17/2015||N+1 Singer||Reiterated Rating||corporate|
Earnings History for Cyprotex plc (LON:CRX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Cyprotex plc (LON:CRX)
Current Year EPS Consensus Estimate: $6.40 EPS
Dividend History for Cyprotex plc (LON:CRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cyprotex plc (LON:CRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cyprotex plc (LON:CRX)
Latest Headlines for Cyprotex plc (LON:CRX)
Cyprotex plc (CRX) Chart for Saturday, July, 22, 2017